|
Headquartered in Basel, Switzerland, Roche Diagnostics is a division of F. Hoffmann-La Roche Ltd (Roche), the world’s largest biotech company with combined strengths in pharmaceuticals and diagnostics. Roche Diagnostics is a leading player in in vitro diagnostics (IVD) – tests performed in a laboratory or at the point-of-care (PoC) on blood and other samples from patients – with a 20% share of the global market. It is also a leader in diabetes management. http://www.bharatbook.com/market-research-reports/medical-devices-market-research-report/roche-diagnostics-medical-device-company-intelligence-report.html This profile focuses on Roche Diagnostics’ PoC activities (part of its Professional Diagnostics business), which produces coagulation monitoring systems, professional blood glucose testing and monitoring systems, cardiac marker testing devices, blood gas/electrolyte testing and urinalysis screening products, and its Diabetes Care business, which produces blood glucose monitoring and insulin delivery systems that are used in hospitals, doctors’ offices or patients’ homes for self-testing. The principal activities of the Professional Diagnostics PoC and Diabetes Care businesses are located in Switzerland, the US, Germany and Austria. In January 2012, Roche began focusing on expanding its coagulation testing product line in North America beyond physicians’ offices and out-patient clinics, with the development of a full line of coagulation analysers for hospitals and reference labs. To achieve this, the company acquired Verum Diagnostica, a Munich, Germany-based company focused on platelet function testing, which is claimed to be the fastest-growing field in the coagulation diagnostics market. The coagulation analyser product line is expected to be introduced in the US and Canada in 2014, subject to regulatory approval and other requirements. Further attempts to expand into North America were made in 2012 with the failed attempt to acquire Illumina Inc, a San Diego, California-based developer of life-science tools and integrated systems for the analysis of genetic variation and function (see Strategic Focus section). Roche believed this acquisition would have secured its position in the sequencing and microarrays market in North America. In 2011, Roche Diagnostics was responsible for 22.9% of the Roche Group’s revenue. This company report provides Overview Key contact information Introduction to the company and its current activities Summary of its financial performance Who are the company’s major competitors? Key recent events in an “at a glance” format Financial Review Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available) Table providing in-depth five-year financial analysis Employee data, including breakdown by company division and geographic location Table of Contents OVERVIEW1 FINANCIAL REVIEW3 First Quarter 2012 Financial Results 3 2011 Financial Results 3 Professional Diagnostics6 Diabetes Care7 Molecular Diagnostics7 Applied Science7 Tissue Diagnostics8 Five-Year Financial Data 9 Outlook 10 Employees 10 STRATEGIC FOCUS11 Operational Excellence Programme11 R&D Strategy 12 PRODUCTS13 Recent Key Events 14 Coagulation Monitoring Systems17 Clinical Chemistry/Immunology Testing Solutions17 Blood Gas Testing Solutions 18 Blood Screening (PCR) 18 Cancer Screening 19 Cardiac Markers 20 Urinalysis Testing Solutions 21 Blood Glucose Testing Solutions 21 Insulin Pumps22 RESEARCH AND DEVELOPMENT 24 R&D Expenditure 24 R&D Activities 24 R&D Facilities 25 R&D Agreements 26 DexCom26 Uppsala BIO26 Merck 27 Clovis Oncology27 Rules-Based Medicine27 Genzyme and OSI Pharmaceuticals27 CapitalBio28 QIAGEN28 Trials and Studies 28 VISION Study28 ATHENA Study29 Accu-Chek 360° View STeP Study29 MANUFACTURING AND DISTRIBUTION31 AGREEMENTS 32 Panasonic Healthcare32 med fusion32 Gen-Probe33 Deutsches Krebsforschungszentrum/University Hospital Heidelberg 33 Cedars-Sinai Medical Center33 DexCom33 Karolinska University Hospital34 LabCorp34 Response Biomedical34 National Health Laboratory Services35 Lonza35 Eisai35 US Department of Defense35 Itamar Medical36 Fluidigm36 Alere36 InterComponentWare36 Exiquon37 Premier37 OraSure Technologies37 Dade Behring (Siemens)38 Iceland Genomics38 MERGERS AND ACQUISITIONS 39 Verum Diagnostica39 mtm laboratories39 PVT Probenverteiltechnik/PVT Lab Systems40 Medical Information Systems Assets40 Medingo40 Disetronic’s Infusion Systems Business41 Amira Medical41 AVL Medical 41 DIVESTITURES 42 Point-of-care non-clinical drugs-of-abuse testing business42 Point-of-care OPTI blood gas analyser product line 42 OTC pregnancy and ovulation self-testing business 42 LITIGATION 43 QIAGEN43 KEY CORPORATE EVENTS 44 For more information kindly visit : Roche Diagnostics Medical Device Company Intelligence Report Or Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Fax: + 91 22 27812290 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: https://twitter.com/BharatBook Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512 http://financemarketreports.blogspot.com/
Related Articles -
Pharmaceuticals, Healthcare, Market Data, Market Research Reports.,
| 
